These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23466360)

  • 41. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial.
    Gomez-Iturriaga A; Casquero F; Pijoan JI; Minguez P; Espinosa JM; Irasarri A; Bueso A; Cacicedo J; Buchser D; Bilbao P
    Radiother Oncol; 2018 Feb; 126(2):278-282. PubMed ID: 29153462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate.
    Kunogi H; Cunha JAM; Chang AJ; Gadzinski AJ; Shinohara K; Hsu IC
    Brachytherapy; 2017; 16(6):1113-1118. PubMed ID: 28869143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
    Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
    Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation between the changes in the EPIC QOL scores and the dose-volume histogram parameters in high-dose-rate brachytherapy combined with hypofractionated external beam radiation therapy for prostate cancer.
    Hashimoto Y; Akimoto T; Iizuka J; Tanabe K; Mitsuhashi N
    Jpn J Clin Oncol; 2015 Jan; 45(1):81-7. PubMed ID: 25425700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: a phase 2 study.
    Salem N; Simonian-Sauve M; Rosello R; Alzieu C; Gravis G; Maraninchi D; Bladou F
    Radiother Oncol; 2003 Feb; 66(2):159-65. PubMed ID: 12648787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
    Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Urinary symptom flare following I-125 prostate brachytherapy.
    Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321.
    Hsu IC; Bae K; Shinohara K; Pouliot J; Purdy J; Ibbott G; Speight J; Vigneault E; Ivker R; Sandler H
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):751-8. PubMed ID: 20207506
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation.
    Hsu IC; Pickett B; Shinohara K; Krieg R; Roach M; Phillips T
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):851-8. PubMed ID: 10705005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms.
    Stock RG; Stone NN; Dahlal M; Lo YC
    Brachytherapy; 2002; 1(2):83-9. PubMed ID: 15062175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of experience and technical changes on acute urinary and rectal morbidity in low-dose prostate brachytherapy using loose seeds real-time implantation.
    Le Fur E; Malhaire JP; Nowak E; Rousseau B; Erauso A; Pene-Baverez D; Papin G; Delage F; Perrouin-Verbe MA; Fournier G; Pradier O; Valeri A
    Brachytherapy; 2013; 12(6):589-95. PubMed ID: 23669150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging.
    Pouliot J; Kim Y; Lessard E; Hsu IC; Vigneron DB; Kurhanewicz J
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1196-207. PubMed ID: 15234056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study.
    Harsolia A; Vargas C; Yan D; Brabbins D; Lockman D; Liang J; Gustafson G; Vicini F; Martinez A; Kestin LL
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1100-9. PubMed ID: 17967304
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiparametric MRI and post implant CT-based dosimetry after prostate brachytherapy with iodine seeds: The higher the dose to the dominant index lesion, the lower the PSA bounce.
    Quivrin M; Loffroy R; Cormier L; Mazoyer F; Bertaut A; Chambade D; Martin E; Maingon P; Walker P; Créhange G
    Radiother Oncol; 2015 Nov; 117(2):258-61. PubMed ID: 26324019
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Temporal resolution of urinary morbidity following prostate brachytherapy.
    Merrick GS; Butler WM; Lief JH; Dorsey AT
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):121-8. PubMed ID: 10758313
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose distribution and morbidity after high dose rate brachytherapy for prostate cancer: influence of V150 and V200 parameters.
    Duchesne GM; Das R; Toye W; See A
    Australas Radiol; 2002 Dec; 46(4):384-9. PubMed ID: 12452909
    [TBL] [Abstract][Full Text] [Related]  

  • 58. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.
    Martínez-Monge R; Moreno M; Ciérvide R; Cambeiro M; Pérez-Gracia JL; Gil-Bazo I; Gaztañaga M; Arbea L; Pascual I; Aristu J
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e469-76. PubMed ID: 22284039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
    Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of intraoperative dosimetry for prostate brachytherapy using registered ultrasound and fluoroscopy.
    Lee J; Hobbs RF; Zahurak M; Ng SK; Zhang Z; Burdette EC; DeWeese TL; Song DY
    Brachytherapy; 2018; 17(6):858-865. PubMed ID: 30217432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.